Previous 10 | Next 10 |
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today provided a regulatory update following receipt of the official meeting minutes from a November 2020 Typ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks limped into the close Friday to finish at session lows, with defensive names including health care and utilities moving just enough to keep the S&am...
Gainers: Medigus (MDGS) +74%.PEDEVCO (PED) +46%.Larimar Therapeutics (LRMR) +23%.Oblong (OBLG) +23%.Blonder Tongue Laboratories (BDR) +21%.BiondVax Pharmaceuticals (BVXV) +19%.Enlivex Therapeutics (ENLV) +19%.Aileron Therapeutics (ALRN) +17%.MoneyGram International (MGI) +15%.ReneSo...
Gainers: Medigus (MDGS) +84%, Altimmune (ALT) +25%, Enlivex Therapeutics (ENLV) +16%, BiondVax Pharmaceuticals (BVXV) +16%, Aileron Therapeutics (ALRN) +15%.Losers: Gossamer Bio (GOSS) -34%, Avenue Therapeutics (ATXI) -17%, Emergent ...
Gainers: iHuman (IH) +44%.Dillard's (DDS) +37%.Acorn International (ATV) +36%.Wah Fu Education (WAFU) +29%.Lizhi (LIZI) +29%.Apex Global Brands (APEX) +25%.WiMi Hologram Cloud (WIMI) +25%.Surface Oncology (SURF) +19%.Skillful Craftsman Education Technology (EDTK) +16%.Reliv' Internationa...
Shares of Fortress Biotech (NASDAQ:FBIO) , a biopharmaceutical company, were down by 22.5% as of 12:26 p.m. EDT on Monday, after dropping by as much as 28.3% earlier in the day. These losses are a result of Avenue Therapeutics (NASDAQ:ATXI) , a majority-owned subsidiary of F...
Avenue Therapeutics (ATXI) craters 56% in premarket after it received a Complete Response Letter ((CRL)) from the FDA regarding its IV tramadol marketing application, intended to treat patients in acute pain who require an opioid.The letter stated that although the Phase 3...
NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced it has received a Complete Response Letter (“CRLȁ...
Are These On Your List Of Penny Stocks To Watch This Week? Whether you’re looking for penny stocks to buy or simply putting a watch list together, you have to start somewhere. Some traders will base their penny stocks list on price only and filter down from there. Oth...
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that a publication entitled “IV tramadol: A novel opt...
News, Short Squeeze, Breakout and More Instantly...
Avenue Therapeutics Inc. Company Name:
ATXI Stock Symbol:
NASDAQ Market:
Avenue Therapeutics Inc. Website:
MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced tha...
MIAMI, May 16, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the ...
– Raised a total of $9.4 million in gross proceeds from warrant exercise transactions since January 2024 – MIAMI, May 15, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutica...